Navigation Links
Amgen Announces Evolocumab (AMG 145) Results From First 52-Week Study Of A PCSK9 Inhibitor To Reduce LDL Cholesterol
Date:11/19/2013

tins (GAUSS-2), as a stand-alone treatment in patients with hyperlipidemia (MENDEL-2), and in patients whose elevated cholesterol is caused by genetic disorders called heterozygous (RUTHERFORD-2) and homozygous (TESLA and TAUSSIG) familial hypercholesterolemia.

Five studies of evolocumab will provide long-term safety and efficacy data, including the FOURIER (Further Cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) study, which will assess whether treatment with evolocumab compared to placebo reduces recurrent cardiovascular events in approximately 22,500 patients with cardiovascular disease.

Additional information about clinical trials of evolocumab can be found at www.clinicaltrials.gov.

About Evolocumab
Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9).1 PCSK9 is a protein that targets LDL receptors for degradation and thereby reduces the liver's ability to remove LDL-C, or "bad" cholesterol, from the blood.6 Evolocumab, being developed by Amgen scientists, is designed to bind to PCSK9 and inhibit PCSK9 from binding to LDL receptors on the liver surface. In the absence of PCSK9, there are more LDL receptors on the surface of the liver to remove LDL-C from the blood.1

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
2. Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013
3. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
4. Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
5. Amgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus
6. Amgen And Servier Complete Product Collaboration Transaction
7. Amgen Announces 2013 Third Quarter Dividend
8. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
9. Amgen And Servier Announce Product Collaboration
10. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
11. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Terascala, the industry ... that Alan Swahn, a former vice president of product ... as vice president of marketing. Terascala’s software when combined ... NetApp create the highest performance and most reliable solutions ... to guide Terascala’s channel expansion and broaden its product ...
(Date:7/10/2014)... Montreal, QC (PRWEB) July 10, 2014 ... comfort and convenience. This rejuvenating device now comes with a ... that develops over time. , The new cup is thinner ... This design works to target rough, thin and uneven surfaces ... original firm cup for a stimulating treatment on areas such ...
(Date:7/10/2014)... -- Kainos Capital, a firm specializing in acquiring and managing ... acquired the Slim-Fast brand from Unilever. Unilever will retain ... transaction were not disclosed. Slim-Fast is a ... ready-to-drink shakes, powders, bars and snacks to retail customers ... the United Kingdom and Ireland.  ...
(Date:7/10/2014)... 2014 -- According to the International Atomic Energy ... comes from terrorists acquiring sufficient quantities of plutonium ... crude nuclear explosive device. The IAEA also notes ... involved gram-level quantities, which can be challenging to ... a new study appearing this week in the ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Kainos Capital Acquires Slim-Fast From Unilever 2Sensitive detection method may help impede illicit nuclear trafficking 2
... 26 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) ... sites in Israel for the planned Phase II dose ... Oxycyte is the company,s perfluorocarbon (PFC) therapeutic oxygen carrier. ... planned for Switzerland."Israeli physicians are excited to be able ...
... 26 Cornerstone Therapeutics Inc. (Nasdaq: CRTX ), a specialty ... the respiratory market, today reported financial results for the year ended December ... Full-Year 2008 Net Revenues more than doubled ... , , , ...
... LASIK Surgeons directory service and website at www.TrustedLASIKSurgeons.com ... seeking to improve their vision and find a highly ... attaining 20-20 vision. What sets the Trusted LASIK ... that only those who are among the best in ...
Cached Biology Technology:Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel 2Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 2Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 3Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 4Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 5Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 6Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 7Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 8Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 9Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 10Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 11Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 12Trusted LASIK Surgeons Welcomes LASIK Expert William Mathers, M.D. of the Casey Vision Correction Center in Portland, Oregon, to Its LASIK Directory 2Trusted LASIK Surgeons Welcomes LASIK Expert William Mathers, M.D. of the Casey Vision Correction Center in Portland, Oregon, to Its LASIK Directory 3Trusted LASIK Surgeons Welcomes LASIK Expert William Mathers, M.D. of the Casey Vision Correction Center in Portland, Oregon, to Its LASIK Directory 4Trusted LASIK Surgeons Welcomes LASIK Expert William Mathers, M.D. of the Casey Vision Correction Center in Portland, Oregon, to Its LASIK Directory 5Trusted LASIK Surgeons Welcomes LASIK Expert William Mathers, M.D. of the Casey Vision Correction Center in Portland, Oregon, to Its LASIK Directory 6Trusted LASIK Surgeons Welcomes LASIK Expert William Mathers, M.D. of the Casey Vision Correction Center in Portland, Oregon, to Its LASIK Directory 7Trusted LASIK Surgeons Welcomes LASIK Expert William Mathers, M.D. of the Casey Vision Correction Center in Portland, Oregon, to Its LASIK Directory 8
(Date:7/11/2014)... explored two different ways that allow unprecedented experimental ... formation of oxygen molecules in photosynthesis. The two ... Nature Communications . , "The new knowledge ... water oxidation, which are key components for building ... solar energy in fuels like hydrogen, ethanol or ...
(Date:7/11/2014)... under the normal circumstances, astrocytes participate in ... environment, and exhibit therapeutic and repairing effects ... studies have found that nerve cells differentiated ... have reduced viability, which produces influences on ... Kailuan General Hospital, Hebei United University, China ...
(Date:7/10/2014)... Santa Fe, Albuquerque, and other major cities in New ... with treated municipal wastewater rather than precious potable water ... than 40% of all golf courses receive treated effluent. ... , Additionally, golf courses and homeowners alike fertilize ... in fertilizer is nitrate. A New Mexico State University ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2'Tailored' water -- the latest in lawn care 2
... of grapes (Vitis vinifera) chiefly to make wine, is an ... from the Neolithic and Early Bronze Ages. We have a ... grape harvest leading to the concept of terroir (the range ... nature of the grapes themselves has been less well understood ...
... CRUZ, CA-- No human can survive longer than a few ... gulps of air. Our brains need a constant supply of ... seals, animals that dive and hunt under the Antarctic sea ... minutes, and remain active and mentally alert the whole time. ...
... HOUSTON (Dec. 18, 2007)Researchers at The University of ... between genes regulating glucose metabolism and spina bifida. The ... from parents and their children with that birth defect. ... dozen genes that take part in glucose metabolism to ...
Cached Biology News:Plant geneticists find veritas in vino 2Plant geneticists find veritas in vino 3Why diving marine mammals resist brain damage from low oxygen 2Why diving marine mammals resist brain damage from low oxygen 3Why diving marine mammals resist brain damage from low oxygen 4UT-Houston's Northrup and colleagues uncover genetic link to spina bifida 2
...
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
... kit contains the basic components required for ... natural and recombinant Feline IL-10 in cell ... sufficient materials to run ELISAs on approximately ... conditions are met: The assay is ...
Request Info...
Biology Products: